Novel therapies, including enzastaurin, in the treatment of ovarian cancer.
about
Investigational therapies currently in Phase II clinical trials for the treatment of pelvic serous carcinomas.Efficacy of trebananib (AMG 386) in treating epithelial ovarian cancer.Enzastaurin inhibits ABCB1-mediated drug efflux independently of effects on protein kinase C signalling and the cellular p53 status.Marine-derived protein kinase inhibitors for neuroinflammatory diseases.
P2860
Novel therapies, including enzastaurin, in the treatment of ovarian cancer.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Novel therapies, including enzastaurin, in the treatment of ovarian cancer.
@en
type
label
Novel therapies, including enzastaurin, in the treatment of ovarian cancer.
@en
prefLabel
Novel therapies, including enzastaurin, in the treatment of ovarian cancer.
@en
P2860
P1476
Novel therapies, including enzastaurin, in the treatment of ovarian cancer.
@en
P2860
P304
P356
10.1517/13543784.2014.900542
P407
P577
2014-03-22T00:00:00Z